Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that develop...

Full description

Bibliographic Details
Main Authors: Kelvin Teck-Hong Kuik, Jason Trubiano, Leon J. Worth, Nur-shirin Harun, Daniel Steinfort, Douglas Johnson
Format: Article
Language:English
Published: Elsevier 2014-10-01
Series:Medical Mycology Case Reports
Subjects:
PJP
Pneumocystis
Pneumonitis
Everolimus
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211753914000414
Description
Summary:Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that developed PJP. Diagnosis was based on clinical features and a quantitative polymerase chain reaction for P. jirovecii DNA. Clinicians should consider PJP as a potential cause of pulmonary infiltrates in patients treated with everolimus.
ISSN:2211-7539

Similar Items